000			02364nam a22005777a 4500
008			180831s20182018 xxu||||| |||| 00| 0 eng d
022			_a0028-4793
024			_a10.1056/NEJMoa1808721 [doi]
040			_aOvid MEDLINE(R)
099			_a30145941
245			_aCardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
251			_aNew England Journal of Medicine. 379(12):1107-1117, 2018 09 20.
252			_aN Engl J Med. 379(12):1107-1117, 2018 09 20.
252			_zN Engl J Med. 2018 Aug 26
260			_c2018
260			_fFY2019
265			_saheadofprint
266			_d2018-08-31
268			_aNew England Journal of Medicine. 2018 Aug 26
546			_aEnglish
650			_a*Anti-Obesity Agents/tu [Therapeutic Use]
650			_a*Benzazepines/tu [Therapeutic Use]
650			_a*Cardiovascular Diseases/co [Complications]
650			_a*Hypoglycemia/ci [Chemically Induced]
650			_a*Obesity/dt [Drug Therapy]
650			_a*Overweight/dt [Drug Therapy]
650			_a*Weight Loss/de [Drug Effects]
650			_aAged
650			_aAnti-Obesity Agents/ae [Adverse Effects]
650			_aAortic Valve Insufficiency/ci [Chemically Induced]
650			_aBenzazepines/ae [Adverse Effects]
650			_aCardiovascular Diseases/ci [Chemically Induced]
650			_aCardiovascular Diseases/ep [Epidemiology]
650			_aDiabetes Mellitus, Type 2/co [Complications]
650			_aDouble-Blind Method
650			_aFemale
650			_aFollow-Up Studies
650			_aHumans
650			_aHypertension, Pulmonary/ci [Chemically Induced]
650			_aMale
650			_aMiddle Aged
650			_aObesity/co [Complications]
650			_aOverweight/co [Complications]
650			_aRisk Factors
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
700			_aWeissman, Neil J
790			_aBohula EA, Bonaca MP, Brown C, Budaj A, CAMELLIA-TIMI 61 Steering Committee and Investigators, Dhadda S, Fanola CL, Francis B, Garcia-Castillo A, Gupta M, Im K, Inzucchi SE, Keech AC, Kuder J, Leiter LA, McGuire DK, Miao W, Patel T, Perdomo C, Qamar A, Ruff CT, Sabatine MS, Scirica BM, Smith SR, Weissman NJ, White HD, Wiviott SD
856			_uhttps://dx.doi.org/10.1056/NEJMoa1808721 _zhttps://dx.doi.org/10.1056/NEJMoa1808721
942			_cART _dArticle
999			_c3695 _d3695